CCDS-O practice question 17 of 25

Which diagnosis and treatment plan may generate a query?

Full set: 140 questions
Answer options
A: Prostate carcinoma and luteinizing hormone-releasing hormone
B: Atrial fibrillation and amiodarone
C: Malnutrition and parenteral nutrition
D: Severe major depressive disorder and immunotherapy Correct answer
Correct Answer:
D. Severe major depressive disorder and immunotherapy
Explanation

A query is generated when documentation is conflicting, ambiguous, or incomplete. The combination of "Severe major depressive disorder" and "immunotherapy" represents a significant clinical inconsistency. Immunotherapy is a treatment primarily used for cancers and some autoimmune diseases; it is not a standard or approved treatment for major depressive disorder. This discrepancy between the diagnosis and the treatment plan would necessitate a query to the provider to clarify the patient's condition, confirm the treatment's rationale, or correct a potential documentation error.

Why Incorrect

A. Luteinizing hormone-releasing hormone (LHRH) agonists are a standard androgen deprivation therapy for prostate carcinoma. This is a clinically consistent pairing.
B. Amiodarone is a common antiarrhythmic medication used to manage and treat atrial fibrillation. This is a clinically consistent pairing.
C. Parenteral nutrition is a standard intervention for patients with malnutrition who cannot tolerate enteral feeding. This is a clinically consistent pairing.

References

1. National Comprehensive Cancer Network (NCCN). (2023). NCCN Clinical Practice Guidelines in Oncology: Immune Checkpoint Inhibitors. Version 1.2023. This peer-reviewed guideline outlines the approved oncologic indications for various immunotherapies, none of which include psychiatric disorders.

2. American Psychiatric Association (APA). (2010). Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition. This guideline details standard treatments (psychotherapy, pharmacotherapy, ECT), which do not include immunotherapy. DOI: https://doi.org/10.1176/appi.books.9780890423387

Scroll to Top